Atlas market file · Equity · United States
Spyre Therapeutics, Inc.SYRE
- Last close
- 103.42
- Change
- -0.89%
- 96-bar range
- 40.91 – 108.14
- As of
- 6 Aug 2026
Spyre Therapeutics, Inc. is a pharmaceutical preparations issuer listed as SYRE on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
SYRE
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+305.09% over the window).
Source rail: Yahoo Finance chart API (SYRE). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for SYRE. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
Atlas Pro artifact
SYRE Market Snapshot PDF
The latest snapshot audit passed. Atlas checks entitlement and evidence again when the PDF is requested.
Atlas Pro entitlement required. The release gate runs again when you request the file.
SYRE public profile
Pharmaceutical preparations issuer. Spyre Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
Spyre Therapeutics, Inc. trades as SYRE on NASDAQ. Spyre Therapeutics, Inc. (SYRE) has a latest verified close of 103.42, down 0.89%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files SYRE under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Spyre Therapeutics, Inc. today
Spyre Therapeutics (SYRE) reported a net loss of $69.0M for Q1 2026, with operating cash outflows of $57.4M, raising questions about its ability to sustain operations without further capital raises. The company’s cash reserves stood at $97.2M as of March 31, 2026, down from prior periods, despite no revenue reported in its latest annual filing.
Spyre positions itself as a leader in next-generation immunology therapies, focusing on inflammatory bowel disease (IBD) treatments. Its pipeline includes SPY002, an anti-TL1A monoclonal antibody, which reported Phase 2 Part A induction results in June 2026. However, the lack of commercial products and reliance on clinical trial success creates significant execution risk.
Recent SEC filings highlight insider share sales and a shelf registration for potential future equity offerings. The company’s S-3ASR filing authorizes sales of up to $250M in securities, signaling preparedness for dilution. Meanwhile, its website emphasizes 'delivering more complete disease control,' but the source requires readers to weigh this optimism against cash burn rates and lack of near-term revenue visibility.
The stock’s volatility reflects biotech sector dynamics: SPY002’s trial data could catalyze movement, but without partnership deals or FDA breakthrough designations, Spyre remains a speculative bet. Analysts will watch Q2 cash flow updates and any guidance on SPY002’s Phase 3 timeline.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
SYRE technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on SYRE
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep SYRE research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
SYRE FAQ
What is Spyre Therapeutics, Inc. (SYRE)?Spyre Therapeutics, Inc. (SYRE) has a latest verified close of 103.42, down 0.89%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Spyre Therapeutics, Inc. (SYRE) has a latest verified close of 103.42, down 0.89%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for SYRE?Spyre Therapeutics, Inc. (SYRE) has a latest verified close of 103.42, down 0.89%, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
Spyre Therapeutics, Inc. (SYRE) has a latest verified close of 103.42, down 0.89%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files SYRE under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the SYRE page updated?The SYRE public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The SYRE public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for SYRE?The SYRE file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:SYRE. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The SYRE file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:SYRE. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on SYRE?Yes. The workstation can open SYRE, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open SYRE, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this SYRE page investment advice?No. The SYRE page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The SYRE page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →